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Abstract
The Ras-guanyl nucleotide exchange factor RasGRP1 plays a critical role in T cell receptor-mediated Erk activation. Previous
studies have emphasized the importance of RasGRP1 in the positive selection of thymocytes, activation of T cells, and
control of autoimmunity. RasGRP1 consists of a number of well-characterized domains, which it shares with its other family
members; however, RasGRP1 also contains an ,200 residue-long tail domain, the function of which is unknown. To
elucidate the physiological role of this domain, we generated knock-in mice expressing RasGRP1 without the tail domain.
Further analysis of these knock-in mice showed that thymocytes lacking the tail domain of RasGRP1 underwent aberrant
thymic selection and, following TCR stimulation, were unable to activate Erk. Furthermore, the deletion of the tail domain
led to enhanced CD4
+ T cell expansion in aged mice, as well as the production of autoantibodies. Mechanistically, the tail-
deleted form of RasGRP1 was not able to traffic to the cell membrane following stimulation, indicating a potential reason for
its inability to activate Erk. While the DAG-binding C1 domain of RasGRP1 has long been recognized as an important factor
mediating Erk activation, we have revealed the physiological relevance of the tail domain in RasGRP1 function and control
of Erk signaling.
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Introduction
The Ras family proteins are critical components of many
signaling pathways and serve to regulate a variety of cell functions,
such as proliferation and differentiation. The most well-charac-
terized signaling pathway regulated by Ras is the Erk (extracellular
signal-regulated kinases)-MAPK (mitogen activated protein kinase)
pathway. Upon activation, Ras recruits Raf-1, a serine/threonine
kinase, to phosphorylate MEK (MAPK/Erk kinase), which in turn
activates Erk1 and Erk2. In T cells, Ras is activated by two families
of Ras GEFs (guanine exchange factors), RasGRP (Ras guanyl
releasing protein) and Sos (son of sevenless). It was recently shown
that Sos contains an allosteric Ras-GTP binding pocket that binds
to Ras-GTP and enhances Sos activity, suggesting that RasGRP1
may be necessary to prime Sos [1]. Studies analyzing mice
deficient in either RasGRP1 or Sos1 indicate that both GEFs are
critical in thymocyte development [2,3]. These proteins may have
disparate roles in the different stages of thymocyte development as
the ratio of Sos1 to RasGRP1 expression changes dramatically
upon the DN3 to DP transition [3].
RasGRP1 is most highly expressed in T cells but is also detected
in B cells, neuronal cells, and mast cells [4,5]. Like the other
members of the RasGRP family, RasGRP1 contains a catalytic
region, which consists of a REM (Ras exchange motif) and
a CDC25 (cell division cycle 25) domain, a pair of EF hands
(calcium binding), and a C1 domain (DAG binding) [6]. Studies
examining the structural domains of RasGRP1 have shown that
deletion of the C1 domain impairs Ras activation through
disruption of RasGRP1-DAG binding [7,8,9]. However,
RasGRP1 also has a C-terminal tail domain, consisting of about
two hundred amino acid residues [6]. Recently, studies have
implicated two domains, the PT (plasma membrane targeting) and
SuPT (suppressor of PT), located in the C-terminus of RasGRP1
as important mediators of protein localization [10,11]. However,
the physiological relevance of this tail domain and its potential role
in TCR-mediated signaling has yet to be discovered.
The importance of RasGRP1 in TCR signaling was first
suggested in Jurkat T cells, in which overexpression of RasGRP1
enhances Ras/Erk signaling [4]. Correspondingly, analysis of
a RasGRP1-deficient Jurkat line demonstrated that RasGRP1 is
indispensable for antigen receptor- and PMA-triggered Erk
activation. Furthermore, RasGRP1-dependent Erk activation
relies upon its DAG-binding C1 domain [9]. RasGRP1-deficient
mice have severely reduced numbers of single positive thymocytes
and, consequently, very few mature T cells in the periphery, while
B cell development is not affected. Further analysis of RasGRP1
2/
2 thymocytes reveals their inability to activate Erk after
stimulation with phorbol 12-myristate 13-acetate (PMA), a DAG-
analog [2]. Another study has shown that RasGRP1 is essential for
the weak TCR signals necessary for Erk activation during positive
selection. However, stronger signals that induce JNK and p38
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38796activation leading to negative selection can be transmitted
independently of RasGRP1 [12].
Interestingly, RasGRP1
2/2 mice develop an autoimmune
disorder marked by splenomegaly and auto-antibody production.
This disease is primarily mediated by T cells that exhibit several
functional defects [13,14]. Furthermore, this phenotype arises
despite reports that regulatory T cell function is intact and may be
enhanced in RasGRP1
2/2 mice [15]. Contrary to these results,
Priatel et al. assert that this autoimmune condition does not
develop upon backcrossing RasGRP1
2/2 mice onto a B6
background [16]. The reason for these disparate results is
unknown but could be due to differences in the ages of the mice
used or in the environmental conditions in which the mice were
housed.
In accordance with the idea that RasGRP1 regulates autoim-
munity in mice, a study analyzing a cohort of patients with
systemic lupus erythematosus (SLE) discovered 13 new splice
variants of RasGRP1 transcripts, resulting in diminished
RasGRP1 activity in these patients. Also, two SLE patients have
T cells containing very little, if any, RasGRP1 protein, supporting
a role for RasGRP1 in the onset of autoimmunity [17]. Another
study examining microRNA expression in lupus CD4
+ T cells
reveals that RasGRP1 can be targeted by miR-21, ultimately
contributing to the DNA hypomethylation seen in patients with
SLE [18]. Moreover, RasGRP1 is one potential protein whose
structural mutation or deregulated expression could mimic
oncogenic Ras mutations [19], which are detected in many solid
tumors and a subset of T lymphocytic leukemia [20,21,22].
Therefore, understanding the regulation of RasGRP1 and its role
in Erk activation is essential to comprehend the establishment of T
cell tolerance, autoimmunity, and transformation.
Knowing the importance of RasGRP1 in T cell signaling and
that RasGRP1 contains a unique tail domain, we undertook the
task of elucidating the role of this domain in RasGRP1 function.
To accomplish this, we generated RasGRP1
d/d knock-in mice,
which express a form of RasGRP1 lacking the tail domain. While
previous studies have highlighted the irreplaceable role of the C1
domain in RasGRP1-mediated Erk activation, our findings reveal
a novel means by which the tail domain of RasGRP1 regulates
TCR-mediated Ras signaling.
Results
Generation of RasGRP1
d/d mice
To assess the function of the RasGRP1 tail domain, we designed
a targeting construct to generate knock-in mice with the tail
domain deleted, which we designated as RasGRP1
d/d (d=deleted)
mice. Rasgrp1 consists of seventeen exons; we inserted a stop
codon, TGA, into exon 15 to ensure retention of the C1 domain
but deletion of the tail. This insertion site, in addition to being
immediately downstream of a Bgl II restriction site, is located
between the C1 domain and the SuPT domain. Our targeting
vector, as depicted in Figure 1A, was used to transfect ES cells.
Positive clones were then used to generate chimeric mice. To
remove the PGK-Neo cassette, chimeric mice were crossed with b-
actin-Cre transgenic mice to generate RasGRP1
d/+ mice. These
mice were then backcrossed onto a B6 background for ten
generations. Intercrossing RasGRP1
d/+ mice led to RasGRP1
d/
d offspring at an expected ratio with no visible defects in viability,
fertility, or behavior.
Next, we confirmed correct targeting by sequencing a PCR
fragment of RasGRP1 amplified from thymocyte cDNA. Se-
quencing results indicated that a TGA stop codon was correctly
inserted towards the 39 end of exon 15 (data not shown). We also
performed real-time PCR analysis to demonstrate comparable
transcript expression in RasGRP1
+/+ and RasGRP1
d/d DP
thymocytes (Figure 1B). We further analyzed the expression of
the truncated RasGRP1 protein by Western blotting to confirm
successful gene targeting. Western blot analysis of thymocyte
lysates using a monoclonal antibody against the C-terminal
portion of RasGRP1 revealed the presence of endogenous
RasGRP1 in wildtype but not RasGRP1
d/d or RasGRP1
2/2
lysates (data not shown). Blotting with a polyclonal antibody
against the CDC25 domain of RasGRP1 revealed the presence of
faster migrating bands in RasGRP1
d/d thymocyte lysates than in
wildtype samples (Figure 1C). However, expression of mutant
RasGRP1 protein was mildly reduced, by ,30% compared to the
wildtype band volume, suggesting that the deletion of the tail
domain affects RasGRP1 protein stability.
Defective thymic and peripheral development in
RasGRP1
d/d mice
Analysis of 4-week-old RasGRP1
d/d mice revealed a defect in
thymocyte development. Unlike RasGRP1
2/2 mice, which had
a severe decrease in both SP populations, the percentages of
RasGRP1
d/d SP thymocytes were only moderately decreased to
1.3% CD8 SP, compared to 2.4% in wildtype mice, and 4.6%
CD4 SP, relative to 8.7% in wildtype thymuses (Figure 2A).
Whereas total thymic cellularity was not affected in RasGRP1
d/
d mice, the numbers of CD4 and CD8 SP thymocytes were
significantly reduced (Figure 2B). In RasGRP1
2/2 mice, total
thymocyte numbers, along with both SP compartments, were
appreciably decreased. Correspondingly, upregulation of TCRb
and CD69, both known indicators of positive selection, was
impaired in RasGRP1
d/d and RasGRP1
2/2 DP thymocytes
(Figure 2C). While ,6% of wildtype DP thymocytes upregulated
TCRb and/or CD69, that percentage was reduced to ,2.5% and
,1.5%, respectively, in RasGRP1
d/d thymocytes. RasGRP1
2/2
thymocytes had an even greater reduction, only 0.2% upregulated
TCRb and/or CD69. However, TCRb and CD69 expression on
RasGRP1
d/d CD4 and CD8 SP thymocytes was not drastically
reduced, as it was on RasGRP1
2/2 CD4 and CD8 SP cells
(Figure 2D).
In the periphery, the percentages of CD4
+ and CD8
+ T cells in
RasGRP1
d/d mice were decreased, although not to the extent seen
in RasGRP1-deficient mice (Figure 2E). Interestingly, 40% of
RasGRP1
d/d CD4
+ T cells in these young mice had upregulated
CD44 and downregulated CD62L, while only 15% of wildtype
cells exhibited this activated/memory phenotype (Figure 2F). In
contrast, 66% of RasGRP1
2/2 CD4
+ T cells were
CD62L
loCD44
hi, likely a result of homeostatic proliferation
following the entry of T cells into the lymphopenic periphery
seen in these mice. Furthermore, the surface expression of TCRb
on CD4
+ and CD8
+ RasGRP1
d/d T cells was slightly reduced,
although higher than that on RasGRP1
2/2 T cells (Figure 2G).
Despite the defect in conventional T cell development,
RasGRP1
d/d and RasGRP1
2/2 spleens contained distinct
populations of Foxp3
+CD4
+ regulatory T cells (Figure 2H). In
fact, the percent of Foxp3
+ cells in the CD4
+ splenic compartment
was increased from about 11% in wildtype mice to 20–25% in
RasGRP1
d/d and RasGRP1
2/2 mice (Figure 2I). This finding was
in agreement with a previous study which demonstrated normal
regulatory T cell development and suppressor function in
RasGRP1
2/2 mice [15]. These data showed that the deletion of
the tail domain of RasGRP1 led to impaired T cell development,
causing reduced numbers of SP thymocytes and mature conven-
tional T cells.
The RasGRP1 Tail Domain Regulates Erk Activation
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d/
d mice
Although RasGRP1
d/d mice did not have as severe defects in T
cell development as RasGRP1
2/2 mice, they exhibited spleno-
megaly at ,3–4 months of age. At six months of age, spleen
weights were greatly increased in RasGRP1
d/d and RasGRP1
2/2
mice, along with overall cell numbers (Figures 3A and 3B). Despite
the decreased percentages of CD4
+ T cells in younger RasGRP1
d/
d and RasGRP1
2/2 mice, total numbers of CD4
+ T cells were
significantly increased compared to wildtype mice. CD4
+ T cells
preferentially expanded over CD8
+ splenocytes, which were
comparable in total numbers but decreased in percentages
compared to wildtype splenocytes. In wildtype mice, ,35% of
CD4
+ cells were CD62L
loCD44
hi, whereas ,80% of RasGRP1
d/
d and RasGRP1
2/2 CD4
+ T cells were CD62L
loCD44
hi
(Figure 3C). Surface expression of TCRb was also reduced on
RasGRP1
d/d T cells and further reduced on RasGRP1
2/2 T cells
(Figure 3D).
To evaluate systemic irregularities in these mice, we assayed
their serum antibody levels. Although the percentages and
activation status of B cells were similar (data not shown), serum
from RasGRP1
d/d and RasGRP1
2/2 mice contained higher
levels of IgE and IgG1, while other isotypes measured, including
IgG2a, IgG2b, and IgM, were comparable (Figure 3E and data not
shown). We also performed auto-antibody ELISAs using NIH3T3-
coated plates to determine if the RasGRP1 mutation caused an
autoimmune-like disorder. As shown in Figure 3F, serum from
RasGRP1
d/d and RasGRP1
2/2 mice contained a higher amount
of auto-antibodies than that from wildtype mice. Furthermore,
staining NIH3T3 cells with serum from RasGRP1
d/d and
Figure 1. Generation of RasGRP1
d/d mice. (A) Targeting construct showing insertion of a stop codon into exon 15 of rasgrp1. (B) Real-time PCR
analysis of RasGRP1 transcript in DP thymocytes from RasGRP1
+/+ and RasGRP1
d/d mice. (C) Western blot analysis of RasGRP1 expression in DP
thymocyte lysate from RasGRP1
+/+ and RasGRP1
d/d mice. * indicates two RasGRP1 protein isoforms on the SDS-PAGE.
doi:10.1371/journal.pone.0038796.g001
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d/d mice. (A) Representative FACS plots of CD8 versus CD4 expression of total live
thymocytes from 4- week-old mice. (B) Total numbers of thymocytes, CD4 SP, and CD8 SP populations. (C) Expression of TCRb (top) and CD69
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2/2 mice revealed striking nuclear staining (Figure 3G,
top panel). We also detected immune complexes in the kidneys of
RasGRP1
d/d and RasGRP1
2/2 mice (Figure 3G, bottom panel).
These data indicated that T cell tolerance and/or homeostasis
were disrupted upon the loss of the RasGRP1 tail domain,
culminating in auto-antibody production and immune complex
deposition.
Impaired function in RasGRP1
d/d T cells
To determine the role of the RasGRP1 tail domain in T cell
activation, we assayed the ability of RasGRP1
d/d splenic T cells to
respond to stimulation. To assess proliferative capacity, we labeled
splenocytes with CFSE, stimulated them with PMA and
ionomycin (P+I), as well as through the TCR using 2C11, and
harvested the cells after 48 hours. CD4
+ RasGRP1
d/d and
RasGRP1
2/2 T cells had slightly impaired proliferation as
measured by CFSE dilution in response to 2C11 stimulation
(Figure 4A). Upon the addition of P+I, RasGRP1
d/d CD4
+ T cells,
but not RasGRP1
2/2 T cells, were able to proliferate comparably
to wildtype cells. ELISA analysis of secreted IL-2 revealed
a marked decrease in the presence of IL-2 in RasGRP1
d/d and
RasGRP1
2/2 splenocyte cultures, particularly following 2C11
stimulation (Figure 4B). Furthermore, the addition of IL-2 in the
presence of 2C11 did not rescue RasGRP1
d/d and RasGRP1
2/2
CD4
+ proliferation (data not shown).
We next assessed the ability of RasGRP1
d/d and RasGRP1
2/2
CD4
+ T cells to upregulate activation markers. As seen in
Figure 4C, RasGRP1
d/d cells increased CD25 expression follow-
ing 2C11 stimulation, although to a lesser extent than wildtype
cells. The upregulation of CD25 on RasGRP1
2/2 CD4
+ T cells
following 2C11 stimulation was significantly impaired. However,
in response to P+I stimulation, CD4
+ T cells from all three
genotypes were able to upregulate CD25. While CD69 upregula-
tion was only slightly defective in RasGRP1
d/d CD4
+ T cells
following both types of stimulation, RasGRP1
2/2 CD4
+ T cells
had a marked defect in their ability to upregulate CD69. CD8
+ T
cells from RasGRP1
d/d and RasGRP1
2/2 mice behaved similarly
to CD4
+ cells but with a less severe defect in their proliferation and
activation marker upregulation (data not shown). We further
determined the ability of these T cells to produce cytokines by
stimulating splenocytes for 4 hours with P+I before intracellular
staining. Interestingly, ,20% of CD4
+ and over 50% of CD8
+ T
cells from RasGRP1
d/d and RasGRP1
2/2 mice produced IFN-c.
In comparison, ,5% of CD4
+ and ,25% of CD8
+ T cells from
wildtype mice were IFN-c
+ (Figure 4D). None of the T cells made
a significant amount of IL-4 (data not shown).
Diminished Erk activation in RasGRP1
d/d thymocytes
As noted in Figure 2C, RasGRP1
d/d DP thymocytes did not
upregulate TCRb and CD69 to the extent of wildtype cells,
indicating a defect in positive selection. Since Erk activation is
essential for positive selection [23,24,25], we analyzed Erk
phosphorylation in DP thymocytes. Thymocytes were isolated
from three-week-old mice and enriched for DP populations to
eliminate any differences that might arise from unequal numbers
of SP cells. DP thymocytes were then stimulated using anti-CD3/
CD4/CD8 antibodies or PMA. Western blots performed on cell
lysates revealed similar levels of tyrosine phosphorylation of
proteins, with slightly reduced levels of LAT phosphorylation in
RasGRP1
d/d and RasGRP1
2/2 thymocytes (Figure 5A).
RasGRP1
2/2 thymocytes could not activate Erk following both
types of stimulation (Figure 5B). Unexpectedly, despite having only
a slight defect in thymocyte development, RasGRP1
d/d DP
thymocytes had a severely diminished ability to activate the Erk
pathway, signifying major ramifications on positive selection.
These data demonstrated that the tail domain of RasGRP1 is
critical for TCR-mediated Erk activation.
Defective thymic selection in RasGRP1
d/d mice
Considering the impaired thymic development and autoim-
mune disorder seen in our mice, we decided to look more closely
at thymic selection in RasGRP1
d/d mice. We bred RasGRP1
d/
d mice onto the MHC class I-restricted HY TCR transgenic line.
RasGRP1
2/2 mice have similarly been examined on the HY
background with the conclusion that RasGRP1 impacts positive,
but not negative, selection [12]. The HY system allows for the
examination of negative selection in males which express the male-
specific HY antigen, thus causing massive deletion of antigen-
specific DP thymocytes. Similar numbers of thymocytes were
recovered from wildtype HY and RasGRP1
d/d HY mice
(Figure 6A, top left). However, staining of thymocytes revealed
the presence of a significant DP population in RasGRP1
d/d HY
thymuses that was not seen in wildtype HY mice. While only 3%
of thymocytes in wildtype mice were double positive, ,30% of
thymocytes in RasGRP1
d/d HY male mice were CD4
+CD8
+.
However, the CD8 SP compartment was not substantially
increased in male RasGRP1
d/d mice; there was also no increase
in peripheral CD8
+ T cells in the spleens of these mice. We
hypothesized that the lower levels of HY TCR expressed on
RasGRP1
d/d thymocytes accounted for the increased DP com-
partment, although this population did not successfully develop
into CD8 SP cells.
Upon analysis of RasGRP1
d/d HY female mice, we found
a marked defect in positive selection. In wildtype HY females,
thymocytes expressing the antigen-specific TCR are positively
selected, as indicated by an increased percentage of CD8 SP cells.
Female RasGRP1
d/d HY mice, however, contained far fewer CD8
SP thymocytes, decreased from ,10% in wildtype to 2.5% in the
knock-in mice (Figure 6A, right). Fewer CD8
+ HY TCR
+ T cells
were also found in the periphery of RasGRP1
d/d HY mice.
Correspondingly, closer examination of DP thymocytes showed
aberrant expression of the HY TCR, CD69, and CD5, while
maintaining high expression of HSA (Figure 6B).
In order to assess the requirement of the tail domain during
positive selection of MHC class II-restricted TCRs, we crossed
RasGRP1
d/d mice onto the OT-II TCR transgenic background.
Positive selection of OT-II
+ T cells on an I-A
b-background results
in the accumulation of CD4 SP thymocytes that are Vb5
hiVa2
hi.
Analysis of RasGRP1
d/d mice expressing the OT-II-specific TCR
revealed a severe defect in the percentage of CD4 SP thymocytes
(bottom) on DP thymocytes. Numbers indicate the percentage of surface marker positive cells. (D) Cell surface expression of TCRb (top) and CD69
(bottom) on CD4 SP (left) and CD8 SP (right) thymocytes. (E) Representative FACS plot of CD8 versus CD4 on splenocytes from 4-week-old mice. (F)
Surface expression of CD44 and CD62L on live, CD4
+ splenocytes. (G) TCRb expression on CD4
+ (left) and CD8
+ (right) splenocytes. Shaded histogram
represents RasGRP1
2/2, solid black line represents RasGRP1
d/d, and dashed black line represents RasGRP1
+/+ thymocytes. (H) Surface expression of
CD4 and intracellular expression of Foxp3. (I) The percent of Foxp3
+ cells in the CD4 splenic compartment was calculated by dividing the percent of
Foxp3
+CD4
+ cells by the total percent of CD4
+ cells. Two-tailed t test; *, p,0.05; **, p,0.005. Data are representative of at least four independent
experiments.
doi:10.1371/journal.pone.0038796.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38796Figure 3. Splenomegaly and autoimmunity in aged RasGRP1
d/d mice. (A) Spleen weights from 6-month-old mice. (B) Numbers of total, CD4
+,
and CD8
+ splenocytes. (C) Representative FACS plots of CD4 versus CD8 on live splenocytes (top), as well as CD62L and CD44 expression on CD4
+
splenocytes (bottom). (D) TCRb expression on RasGRP1
2/2 (shaded histogram), RasGRP1
d/d (solid black line), and RasGRP1
+/+ (dashed black line)
splenocytes (left). (E–F) Blood serum levels of IgE, IgG1 (E), and anti-nuclear antibodies (F) from RasGRP1
2/2 (triangles), RasGRP1
d/d (squares), and
RasGRP1
+/+ (circles) mice. (G) Top panel, auto-antibodies were detected by immunostaining slides with fixed NIH3T3 cells with mouse serum,
followed by FITC-conjugated anti-mouse IgG. Bottom panel, immune complex deposition in the glomeruli of mice was visualized by staining kidney
cryosections with FITC-conjugated anti-mouse IgG. Imaging was performed using light or fluorescent microscopy at 10x magnification. Two-tailed t
test; *, p,0.05; **, p,0.005. Data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0038796.g003
Figure 4. Aberrant T cell proliferation, activation, and cytokine production in RasGRP1
d/d mice. (A) Splenocytes were isolated from six to
eight-week-old mice and stained with 5 mM CFSE and stimulated as shown. After forty-eight hours, cells were harvested and stained for CD4 and CD8.
Histograms shown are gated on CD4
+ cells. Shaded histogram represents RasGRP1
2/2, solid black line represents RasGRP1
d/d, and dashed black line
represents RasGRP1
+/+ splenocytes. (B) Supernatant from the CFSE culture was collected after 24 hours and used to perform an IL-2 ELISA. (C) Cells
were stimulated as in (A) but harvested after twenty-four hours and analyzed by FACS for CD4, CD8, CD69, and CD25 expression. Shaded histogram
represents RasGRP1
2/2, solid black line represents RasGRP1
d/d, and dashed black line represents RasGRP1
+/+ CD4
+ splenocytes. (D)Splenocytes from
six-week-old mice were harvested and stimulated with P+I with Monensin for 4 hours. Left: Representative FACS plots of splenocytes stained with
7AAD, CD4, CD8, and IFN-c. Right: Quantitative representation of the percent of CD4 and CD8 cells from each genotype that made IFN-c following in
vitro P+I stimulation. Two-tailed t test; *, p,0.05; **, p,0.005. Data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0038796.g004
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d/+ OT-II
+ thymocytes
were CD4 SP cells, RasGRP1
d/d OT-II
+ thymuses contained only
,2% CD4 SP cells. Furthermore, while over 90% of RasGRP1
d/+
OT-II
+ CD4 SP cells stained positive for the Va2 TCR, only
38.7% of RasGRP1
d/d OT-II
+ CD4 SP cells expressed this TCR.
This diminution could be accounted for by either decreased
surface TCR expression or the presence of endogenously rear-
ranged TCRs. Likewise, the spleens of RasGRP1
d/d OT-II
+ mice
contained far fewer CD4
+ and Va2
+ T cells (Figure 6C, right).
Collectively, our data from these two different TCR transgenic
lines indicated that the tail domain of RasGRP1 is critical for
proper positive and negative selection.
Impaired localization of RasGRP1Dtail in T cells
In an attempt to elucidate the mechanism by which the tail
domain regulates RasGRP1 function and Erk activation, we
investigated RasGRP1 translocation following stimulation. Differ-
ent studies have focused on the localization of RasGRP1 and the
ramifications this may have on Ras activation [8,10,26,27,28]. We
wanted to determine if the loss of the tail domain would impact
RasGRP1 localization using Jurkat T cells. We electroporated
Jurkat cells with GFP-tagged rasgrp1 wildtype or Dtail construct
and performed live cell imaging. The GFP-RasGRP1 wildtype
protein was initially found either in the cytoplasm or on the plasma
membrane depending upon the level of protein expression
(Figure 7). Following stimulation through the TCR via OKT3
or using PMA, GFP fluorescence moved to or intensified at the
plasma membrane. In contrast, GFP-RasGRP1Dtail was initially
seen throughout the entire cell, including the nucleus. Following
OKT3 stimulation, GFP fluorescence failed to move. Interestingly,
after the addition of PMA, GFP-RasGRP1Dtail consistently
localized in a perinuclear pattern. This aberrant localization was
not driven by the GFP tag seeing as similar experiments using
Flag-tagged RasGRP1 and RasGRP1Dtail constructs yielded
identical results (data not shown). This dramatic defect in protein
translocation could account for the inability of the truncated
RasGRP1 protein to activate the Ras-Erk pathway.
Discussion
Recent publications have investigated the roles of the PT
(Plasma membrane Targeter) and SuPT (Suppressor of PT)
domains, both of which are included in the tail domain. The PT
domain was found to be sufficient and necessary for antigen
receptor-mediated plasma membrane translocation of RasGRP1
in several B cell lines [10]. A follow-up study defined the precise
mechanism by which the PT domain regulates plasma membrane
targeting. The authors demonstrate that a small segment of the PT
domain, which is enriched in basic/hydrophobic residues, binds
directly to PI3K-generated products [11]. In this report, we
demonstrated that the tail domain of RasGRP1 was essential for
its function in T cell development and activation in vivo. The
deletion of the tail domain had a significant impact on thymocyte
development and T cell function. RasGRP1
d/d T cells were
Figure 5. Diminished Erk activation in RasGRP1
d/d DP thymocytes. (A–B) Enriched DP thymocytes were stimulated as shown. Lysates were
analyzed via SDS-PAGE and immunoblotting for overall tyrosine phosphorylation (pY) and LAT (A) or pErk and Erk2 (B).
doi:10.1371/journal.pone.0038796.g005
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38796intermediary between wildtype and knockout profiles in terms of
thymocyte subset percentages and surface marker expression.
Despite only a slight defect in T cell development, Erk activation
was drastically impaired in RasGRP1
d/d DP cells. Furthermore,
crossing upon the OT-II and HY transgenic TCR backgrounds
led to the near-complete block in positive selection. And, as
RasGRP1
d/d mice aged, they more closely resembled RasGRP1
2/
2 mice in CD4
+ T cell percentages, ability of those T cells to
produce IFN-c, and high levels of serum IgE.
In RasGRP1
d/d T cells, the remaining RasGRP1 domains may
have been able to bypass the need for the tail domain and account
for some level of development and activation. The GEF and REM
domains are likely required for membrane localization through
their binding to Ras, which is anchored in endomembranes or the
plasma membrane [29,30]. Also, the calcium-binding EF hands
and the SuPT domain are able to affect plasma membrane
targeting of RasGRP1 [10,29]. Furthermore, the C1 domain
mediates both internal membrane and plasma membrane
targeting [10,28]. When the C1 domain is deleted in B cell lines,
plasma membrane targeting of RasGRP1 still occurs, albeit with
significantly reduced efficiency [10]. In some circumstances, signal
strength may be enough to recruit RasGRP1 through its
remaining domains, but, with a lower level or different form of
signaling, the tail domain may be indispensable. In this manner,
we speculate that RasGRP1
d/d T cells with a stronger affinity than
normal for self-antigen were able to bypass the need for intact
RasGRP1 activity and develop into mature T cells.
Additional evidence supporting our claim that the tail domain is
essential for RasGRP1 function came from our assessment of T
cell function and autoimmunity in RasGRP1
d/d mice. RasGRP1
d/
d T cells exhibited defects in their proliferative capacity, IL-2
production, and upregulation of activation markers, particularly in
response to TCR stimulation. Interestingly, despite high levels of
serum IgE, T cells from RasGRP1
d/d and RasGRP1
2/2 mice had
an increased propensity to produce IFN-c, but not IL-4, upon
stimulation. A report examining TCR-stimulated human cells
asserts that naı ¨ve CD45RO
2 T cells stimulated briefly via the
TCR produce high levels of IFN-c, but no IL-4, inducing B cells to
generate IgE [31]. Alternatively, as seen in Itk
2/2 mice [32], cd T
cells could be inducing IgE production by B cells in our mice.
While autoimmunity in RasGRP1
2/2 mice has been demon-
strated previously [13,14], a conflicting report proposes that those
results stem from the mixed background of the mice analyzed [16].
The mice used in the studies described here were backcrossed onto
the B6 background for ten generations. By six months of age, the
CD4 compartment had expanded significantly and serum from
these mice contained high levels of auto-antibodies. From our
results, we concluded that the deletion or truncation of RasGRP1
protein impaired thymic selection and/or T cell homeostasis such
that these mice indeed developed an autoimmune disorder. The
issue of how disrupting RasGRP1 function seems to selectively
affect CD4
+ T cells remains unknown. It has been shown that the
CD4
+ T cell lineage relies more heavily upon Erk signaling [23,33]
and perhaps the loss of RasGRP1 function had more severe
ramifications on CD4
+ rather than CD8
+ T cells.
Surprisingly, it seems as though peripheral tolerance in these
mice was not affected. A previous study documents the functional
suppressive nature of RasGRP1
2/2 regulatory T cells [15]. In
accordance with this work, unpublished studies in our lab showed
that RasGRP1
2/2 T cells were able to suppress LATY136F T cell
expansion upon co-transfer into lymphopenic mice. Also, the
percentage of Foxp3
+ T cells among the CD4 T cell populations
from both RasGRP1
2/2 and RasGRP1
d/d spleens were actually
increased compared to wildtype mice (Figure 2I). Regulatory T
cells are thought to be selected based on their intermediate affinity
for self-ligands in the thymus [34,35]. The signaling pathways
guiding conventional and regulatory T cell development may be
Figure 6. Negative and positive selection defects in RasGRP1
d/d mice. (A) Total thymocytes and splenocytes from wildtype and RasGRP1
d/
d male and female mice expressing the HY TCR transgene were analyzed for the expression of CD4, CD8, and the transgenic TCR chain used by the HY
TCR. Numbers above the plots indicate the total number of thymocytes. N=6–9 mice per group. (B) DP and CD8 SP thymocytes from female mice
expressing the HY TCR were analyzed for expression of the HY TCR, HSA, CD69, and CD5. The shaded histogram represents wildtype cells while the
solid line indicates RasGRP1
d/d thymocytes. (C) Thymocytes and splenocytes from wildtype and RasGRP1
d/d mice expressing the OT-II TCR were
analyzed for the expression of CD4 and CD8. Representative histograms show the levels of Va2 on either CD4 SP or CD4
+ splenocytes. The data are
representative of four independent experiments.
doi:10.1371/journal.pone.0038796.g006
Figure 7. Impaired localization of the RasGRP1Dtail construct in Jurkat T cells. Jurkat cells were electroporated with GFP-RasGRP1 or GFP-
RasGRP1Dtail plasmids. Live cell imaging was performed on a Zeiss Observer D1 station equipped with a CoolSNAPHQ charge-coupled device camera
(Roper Scientific) and a high-speed automatic objective stage for multiple Z stack recording. The images were collected with a 40x objective lens and
2.5x camera zoom at 45 second intervals at 37uC. For each cell at each time point, GFP data were collected over 21 continuous vertical Z positions.
After the first time frame, OKT3 or PMA were added to the samples. Images were processed by 3D deconvolution using AutoQuant X software (Media
Cybernetics). All imaging manipulation and analysis were done using the MetaMorph software suite (Molecular Probes). Data are representative of at
least six independent experiments analyzing at least five cells per experiment.
doi:10.1371/journal.pone.0038796.g007
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to bypass the need for RasGRP1 during its maturation.
Our data clearly showed that deletion of the tail domain
affected RasGRP1 protein expression so that it was expressed at
about 70% of the level of wildtype protein. A similar effect was
seen in human SLE patients [17]. In this study, it was shown that 9
of 13 new splice variants of the human RasGRP1 gene contain
a form of RasGRP1 that lacks exons 16 and 17, which comprise
most of the tail domain, either alone or in conjunction with other
RasGRP1 exons. Moreover, this report shows that the RasGRP1
protein level is reduced in these patients. Thus, our RasGRP1
d/
d line should be an excellent model to study the human diseases
caused by splice variations in the human RasGRP1 gene. While it
is possible that the reduced expression of RasGRP1 protein may
contribute to the functional defect in RasGRP1
d/d mice,
RasGRP1
+/2 cells express a much reduced level of wildtype
protein but function normally [2], indicating that the defect
observed in RasGRP1
d/d mice was a true consequence of the tail
domain deletion. Moreover, our data with Jurkat cells clearly
showed that deletion of this tail domain impaired RasGRP1
membrane localization. While wildtype GFP-RasGRP1 was
concentrated on the plasma membrane, GFP-RasGRP1Dtail was
seen throughout the cell and failed to move following TCR
engagement. After PMA stimulation, GFP-RasGRP1Dtail moved
into a perinuclear pattern, perhaps reflecting the tendency of the
C1 domain to accumulate at endomembranes [8,10,28]. Thus, our
data in vivo and in vitro implicate an important role for the tail
domain in controlling T cell development and autoimmunity. Our
study reveals the novel findings that Erk activation in T cells is
dependent upon the tail domain of RasGRP1 and that the loss of
the RasGRP1 tail domain has severe consequences on thymocyte
selection and T cell function.
Materials and Methods
Ethics Statement
All experiments with mice were conducted in accordance with
National Institutes of Health guidelines. The experiments de-
scribed here were reviewed and approved by the Duke University
Institutional Animal Care Committee (Permit Number: A191-11-
07).
Generation of RasGRP1
d/d knock-in mice
RasGRP1 genomic fragments were amplified from embryonic
stem (ES) cells by PCR, sequenced, and cloned into the targeting
plasmid (Figure 1). The short arm contained a 1.8-kb sequence
including exon 14 and a modified exon 15 with a premature stop
codon to delete amino acids 669–852. The long arm was
comprised of a 4.2-kb sequence including exon 16 and surround-
ing introns. After transfection, G418-resistant ES cells were
screened by PCR. The correctly targeted ES cells were injected
into blastocysts to generate chimeric mice. To delete the PGK-
Neo cassette, chimeric mice were crossed with b-actin-Cre mice to
produce RasGRP1
d/+ mice. These mice were subsequently
backcrossed with C57BL/6 mice for ten generations. Genotyping
of littermates was done by PCR using the following primers: 59-
CAT GAA AGC CAT CGG GTA CT-39 and 59-AAG ATC
CTT CTT CGG GTG CT-39. To confirm the insertion of
a premature stop codon in exon 15, RasGRP1 RNA was amplified
by reverse transcription (RT)-PCR using two primers: 59-TGA
CAA CTG TGC TGG CTT TC-39 and 59-ACG ATT CTG
TTT GGG TGC TC-39. C57/BL6 mice, OT-II mice, and b-
actin-Cre mice were purchased from Jackson Laboratory. HY-
TCR transgenic mice were purchased from Taconic Farms. Mice
were housed in specific pathogen-free conditions.
Western blot and real-time PCR analysis
To confirm equal expression of RasGRP1 mRNA, DP
thymocytes were sorted and used for total RNA extraction using
Trizol reagents. cDNAs were synthesized using SuperScript
reverse transcriptase (Invitrogen) using oligo-dT as the primer.
Quantification of RasGRP1 RNAs was performed by real-time
PCR with SYBR Green Super Mix (Bio-Rad) using the following
primers: 59-AGG ATG CCC TGG AAA AGA AT-39 and 59-
AGC TGG CAT CCA TCT TGA AC-39. For Western blot
analyses, 5610
7 thymocytes or splenocytes were lysed in 1 mL of
RIPA buffer. The lysates were resolved on SDS-PAGE and
probed with a RasGRP1 monoclonal antibody (Santa Cruz) or
polyclonal antisera (J32), which is directed against the catalytic
domain of rat RasGRP1 [4]. We calculated wildtype and mutant
RasGRP1 band volumes as a ratio of Erk2 expression using
Gausssian deconvolution through the Phoretix 1D gel analysis
software (TotalLab Limited).
FACS analysis and antibodies
Fluorescent antibodies used in flow cytometry, such an anti-
CD4, -CD8, -CD25, -CD44, -CD62L, -HY TCR, -TCRb s-HSA,
and -Va2, were all purchased from eBioscience or BioLegend. For
surface marker staining, single-cell suspensions were prepared
from thymuses or spleens and were blocked with 2.4G2 (anti-
FccII/III receptor) before staining with different antibody
mixtures. For intracellular Foxp3 staining, splenocytes were
prepared and stained for surface markers as above. They were
then fixed and permeabilized with the eBioscience Foxp3 staining
kit before being stained with anti-Foxp3 (eBioscience). For
intracellular staining of cytokines, cells were isolated and
stimulated with PMA (20 ng/mL) and ionomycin (0.5 mg/mL)
for one hour before the addition of Monensin. Cells were left for
three additional hours before being fixed and permeabilized per
the manufacturer’s instructions (eBioscience). Cells were then
stained with anti-IFN-c and -IL-4. Flow cytometry data were
acquired on FACSCanto (BD Biosciences) and analyzed with the
FlowJo software.
Cell activation, proliferation, and IL-2 production
Splenocytes were stimulated with plate-coated anti-CD3 (3 mg/
mL 2C11) or with PMA (20 ng/mL) and ionomycin (0.5 mg/mL)
overnight to assess upregulation of activation markers. Cells were
then stained with antibodies against CD4, CD8, CD25, CD69,
and 7AAD and analyzed via flow cytometry. To determine cell
proliferation, splenocytes were loaded with 5 mM CFSE and
stimulated with 2C11 or PMA and ionomycin as above. After
forty-eight hours, cells were harvested, stained, and analyzed by
flow cytometry for CFSE dilution. For IL-2 production, at twenty-
four hours after stimulation, 50 mL of supernatant was collected
and analyzed by ELISA using IL-2 capture and detection
antibodies according to the manufacturer’s instructions
(eBioscience).
Serum immunoglobulin and autoimmunity analysis
For serum antibody detection, sera were serially diluted as
shown. 96-well plates were coated with anti-mouse IgE and
Ig(H+L) and incubated with serum, followed by detection
antibodies. For autoantibody detection, 96-well plates were coated
with NIH3T3 cells and incubated with serum followed by anti-
mouse IgG-HRP. Absorbance at 405 nm (anti-IgE and autoan-
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a precision microplate reader (Molecular Devices). For anti-
nuclear antibody fluorescent staining, NIH3T3 cells were blocked
with 2.4G2 and then incubated with serum (1:50) followed by
FITC goat anti-mouse IgG. Immune complex deposition in mice
was detected by staining cryosections of kidneys with FITC-
conjugated goat anti-mouse IgG. Slides were visualized by
fluorescent microscopy.
DP thymocyte isolation, activation, and Western blot
analysis
DP thymocytes were enriched using the EasySep biotin
selection kit (StemCell Technologies). Briefly, thymocytes were
blocked using anti-mouse FcR antibody and then incubated with
biotin-conjugated H2-D
b antibody (BioLegend). Cells were mixed
with biotin selection cocktail and magnetic beads, per the
manufacturer’s instructions, to remove SP and DN cells which
express high levels of MHC class I. Selected thymocytes were then
stimulated directly with 20 ng/mL PMA or were incubated with
10 mg/mL biotin-aCD3 and 2.5 mg/mL biotin-aCD4/CD8 and
activated by cross-linking with 25 mg/mL streptavidin (Sigma).
The cells were lysed at the indicated time points in RIPA lysis
buffer. Cell lysates were resolved using SDS-PAGE and trans-
ferred onto nitrocellulose membranes (BioRad). Membranes were
then blotted with anti-pTyr (Upstate Biotechnology), anti-LAT,
anti-pErk (Cell Signaling Technology), and anti-Erk2 (Santa Cruz
Biotechnology). For secondary antibodies, AlexaFluor 680 anti-
mouse or anti-rabbit IgG (Molecular Probes) or IRDye 800 anti-
rabbit (Rockland) were used. The membranes were scanned using
the LI-COR Odyssey infrared imaging system.
GFP-RasGRP1 imaging
The cDNA sequences of mouse rasgrp1 and rasgrp1Dtail (lacking
amino acids 665–852) fused to GFP were cloned into the pHSIB
retroviral vector. Jurkat cells were electroporated with 10 mgo f
plasmid DNA. Live cell imaging was performed on a Zeiss
Observer D1 station equipped with a CoolSNAPHQ charge-
coupled device camera (Roper Scientific) and a high-speed
automatic objective stage. Images were collected with a 40x
objective lens and 2.5x camera zoom at 45 second intervals. For
each cell at each time point, GFP data were collected over 21
continuous vertical Z positions. After 45 seconds, OKT3 or PMA
were added to the samples. Images were processed by 3D
deconvolution using AutoQuant X software (Media Cybernetics).
Imaging manipulation and analyses were done using the
MetaMorph software suite (Molecular Probes).
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